Zenas BioPharma
ZBIO
145 hedge funds and large institutions have $1.55B invested in Zenas BioPharma in 2026 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 62 increasing their positions, 39 reducing their positions, and 22 closing their positions.
1,455% more call options, than puts
Call options by funds: $7.57M | Put options by funds: $487K
59% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 39
35% more capital invested
Capital invested by funds: $1.14B → $1.55B (+$404M)
32% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 22
4% more funds holding
Funds holding: 140 → 145 (+5)
0% more funds holding in top 10
Funds holding in top 10: 8 → 8 (0)
3.68% less ownership
Funds ownership: 100.72% → 97.04% (-3.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$17.3M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$16.8M |
| 3 |
BlackRock
New York
|
+$12.9M |
| 4 |
State Street
Boston,
Massachusetts
|
+$11.6M |
| 5 |
Two Sigma Investments
New York
|
+$10.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$12.4M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$10.2M |
| 3 |
JFG
Jefferies Financial Group
New York
|
-$4.3M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$3.76M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$3.55M |
ZBIO Hedge Fund Activity: Q2 2026 in Review
145 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Zenas BioPharma (ZBIO) for Q2 2026, worth a combined $1.55B — up 35% from $1.14B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new ZBIO positions and 22 closed out — a net gain of 7 holders — while 62 added to existing stakes and 39 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $17.3M. The largest seller was Silverarc Capital Management, cutting an estimated $12.4M.
- 145 institutional investors held Zenas BioPharma (ZBIO) as of Q2 2026, up from 140 in Q1 2026.
- Funds reported $1.55B of Zenas BioPharma stock for Q2 2026, up 35% quarter-over-quarter.
- 29 funds opened new Zenas BioPharma positions in Q2 2026 and 22 closed out, a net change of +7 holders.
- The largest Zenas BioPharma buyer in Q2 2026 was T. Rowe Price Associates, an estimated $17.3M added.
- The largest Zenas BioPharma seller in Q2 2026 was Silverarc Capital Management, an estimated $12.4M sold.
Based on aggregated 13F filings for Q2 2026.